Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 299 participants.
Also called NCT02458287
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 299 participants
- Sponsor
- Registry
-
NCT02458287
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02458287. Randomized; quadruple masking; primary purpose treatment. Start 2015-06 (actual); primary completion 2016-02 (actual). Results posted on 2017-12-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia
- Acronym
- SPIRE-AI
- Condition
- Hyperlipidemia
- Intervention (Biological)
- Bococizumab 150mg
- Intervention (Biological)
- Bococizumab 75mg
- Intervention (Biological)
- Bococizumab 150mg placebo
- Intervention (Biological)
- Bococizumab 75mg placebo
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct02458287- Content hash
07540e13ca2aff6c73545b0d70287a4de0775685cbd9718db2457fd0a7e66ee4